Business · Companies · 7 hrs ago
Novartis ends research partnership with BioArctic
Novartis has ended its research partnership with BioArctic, a Swedish biotechnology company.
The collaboration, agreed in August 2025, aimed to combine BioArctic’s BrainTransporter technology with a Novartis antibody that was not publicly specified.
BioArctic said Novartis made the decision to end the partnership.
It said the decision was not related to the BrainTransporter technology.
BioArctic will keep the $30 million upfront payment it received.
The companies did not say what prompted Novartis’s decision or describe any next steps.
Novartis has ended its research collaboration with Swedish biotech company BioArctic.
The partnership, agreed in August 2025, focused on BioArctic’s BrainTransporter technology.
The technology was to be combined with an unspecified proprietary Novartis antibody.
BioArctic said it will keep the $30 million upfront payment.
BioArctic said Novartis alone decided to end the collaboration and that the decision was unrelated to the technology.
- Who
- Novartis and Swedish biotech company BioArctic.
- What
- Novartis ended its research collaboration with BioArctic, focused on BrainTransporter technology.
- When
- The partnership was agreed in August 2025. BioArctic announced the termination on Monday evening, November 2, 2026.
- Where
- Not stated.
- Why
- Not stated. BioArctic said the decision was unrelated to its BrainTransporter technology.
This story does not have two clearly opposing sides.
Novartis and BioArctic agreed to a research collaboration involving BrainTransporter technology and an unspecified Novartis antibody.
BioArctic announced that Novartis had ended the collaboration.
- Partners
- Novartis and BioArctic
- Technology
- BioArctic’s BrainTransporter
- Antibody
- Unspecified proprietary Novartis antibody
- Upfront payment
- $30 million, which BioArctic will keep
- Agreement
- August 2025